SecBot SecBot
8-K ·Filed May 12, 2026

RLMD

RELMADA THERAPEUTICS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001213900-26-055164
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock will trade on the mid-2026 IND filing and RESCUE program start, not on Q1 financials. The $234M cash runway through 2029 removes near-term financing risk. Watch for the IND filing announcement and initial 3-month Phase 3 data expected by YE 2026 as the next catalysts.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.49
T+0 close · May 12, 2026 · via day close
Latest settled
−34.05%
T+60 · $4.94
Vs SPY
−38.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $7.49entry
  2. T+1 · 6mo ago 0.00%α +0.00% · $7.49
  3. T+5 · 6mo ago −6.14%α −4.98% · $7.03
  4. T+20 · 5mo ago −12.95%α −12.34% · $6.52
  5. T+60 · 3mo ago −34.05%α −38.48% · $4.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Relmada Therapeutics reported Q1 2026 results that were in line with its pre-revenue clinical-stage profile, with a net loss of $19.1M ($0.22/share) vs. consensus of $-0.20. The key event is the reiteration of mid-2026 timelines to file the NDV-01 IND and initiate the Phase 3 RESCUE registrational program, supported by a $234M cash balance (post $160M PIPE) funding operations through 2029. The filing is neutral, no financial beat or miss, no guidance change, and the clinical milestones were already telegraphed in the prior quarter's update.

Key Financial Metrics

EPS
−$0.22
est −$0.20 · -10.0%
Rating
in line

Key Facts

  • Q1 2026 net loss of $19.1M ($0.22/share) vs. consensus $-0.20, a 12.8% miss on EPS
  • Cash, cash equivalents, and short-term investments of $234.0M as of March 31, 2026, including ~$150M net from March 2026 PIPE
  • On track to file NDV-01 IND and initiate Phase 3 RESCUE program in mid-2026
  • Filed provisional patent application for NDV-01 in April 2026, with potential protection until 2047
  • 104.9M shares outstanding as of May 7, 2026, up from 73.3M at year-end 2025 due to PIPE issuance
  • No revenue reported, clinical-stage biotech with no approved products

Financial Impact

No revenue; net loss $19.1M in Q1 2026 vs. $17.6M in Q1 2025; cash burn $15.1M in operating cash flow

net losscash burndilution

Risk Factors

  • Phase 3 RESCUE program may fail to replicate Phase 2 efficacy or safety results
  • Dilution risk: 104.9M shares outstanding, up from 30.2M at Dec 2024, with additional options/warrants outstanding
  • No approved products or revenue; entirely dependent on clinical trial success

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-055164
Document: ea029041401ex99-2.htm0001213900-26-055164
Document: ea0290414-8k_relmada.htm0001213900-26-055164
Document: 0001213900-26-055164-index-headers.html0001213900-26-055164
Document: 0001213900-26-055164-index.html0001213900-26-055164
Document: 0001213900-26-055164.txt0001213900-26-055164
8-K Data (Synthetic)0001213900-26-055164

Track record

11 reports on RLMD

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
  4. Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
  5. May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
  6. May 12, 202626w ago 8-K Neutral 4/10 Viewing Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
  7. Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
  8. Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
  9. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
  10. Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026